Exicure (NASDAQ:XCUR) versus NewAmsterdam Pharma (NASDAQ:NAMS) Financial Contrast

Exicure (NASDAQ:XCUR) and NewAmsterdam Pharma (NASDAQ:NAMS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Insider and Institutional Ownership

42.8% of Exicure shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 8.4% of Exicure shares are owned by insiders. Comparatively, 19.5% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Exicure and NewAmsterdam Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	27.15%	15.27%
NewAmsterdam Pharma	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Exicure and NewAmsterdam Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	0	0	0	0	N/A
NewAmsterdam Pharma	0	0	6	0	3.00

NewAmsterdam Pharma has a consensus price target of $33.25, indicating a potential upside of 69.82%. Given NewAmsterdam Pharma’s higher probable upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Exicure.

Volatility & Risk

Exicure has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500.

Earnings and Valuation

This table compares Exicure and NewAmsterdam Pharma’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$28.83 million	0.14	-$2.58 million	$2.11	0.22
NewAmsterdam Pharma	$6.86 million	256.74	-$176.94 million	N/A	N/A

Exicure has higher revenue and earnings than NewAmsterdam Pharma.

About Exicure

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.